This protocol is part of an FDA Individual Patient Expanded Access IND. This study is to be conducted according to US and International Standards of Good Clinical Practice (FDA Title 21 part 312 and International Conference on Harmonization guidelines), applicable government regulations and Hope Biosciences Stem Cell Research Foundation policies and procedures.
This Individual Patient Expanded Access IND has been created per the request of a 65-year-old woman diagnosed with Systemic Lupus Erythematosus (SLE).
Study Type
EXPANDED_ACCESS
Subject has completed 10 infusions and has been authorized for an additional 12 infusions over 1 year.
Hope Biosciences Stem Cell Research Foundation
Sugar Land, Texas, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.